Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07449351) titled 'Psilocybin Microdosing on Cognition, Mood and Quality of Life' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Care Provider).
Primary Sponsor: Yale University
Condition:
Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Intervention:
Drug: Psliocybin
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: April 1, 2026
Target Sample Size: 20
Countries of Recruitment:
United States
To know more, visit https://clin...